Dr Manchanda speaks with ecacer at BCGS 2018 about an economic projection for a large-scale screening effort to identify mutations in genes with a strong link to the onset of breast and gynaecologic cancers.

He highlights data indicating that a significant proportion of eligible participants falling through the gaps, and describes the results from this model as compelling for further validation and consideration in the UK and US.

In terms of cost-effectiveness, Dr Manachanda points to the NICE guidelines of £30,000 per QALY, and that the prevention and early diagnosis of cancers in such a screening initiative come in below this threshold.

Dr Manachanda also spoke with ecancer about the PROTECTOR study, here.